Role of the Oral Microbiome in Blood Pressure Regulation in Pregnancy

April 26, 2019 updated by: Dr Jenny Myers, University of Manchester

Investigation of the Oral Microbiome in Pregnancy - do Differences in Oral Bacterial Profiles and Nitrate Metabolism Contribute to Blood Pressure Regulation in Pregnant Women?

High blood pressure in pregnancy is associated with poor outcomes for both mum and baby, increasing the risk of pregnancy complications including pre-eclampsia, fetal growth restriction and preterm birth. The development of new blood pressure lowering interventions suitable for use in pregnancy is a key research priority.

Inorganic nitrate is a compound found in certain types of food, particularly green leafy vegetables and beetroot. Nitrate provides an important source of nitric oxide (NO), a molecule involved in keeping blood vessels healthy and regulating blood pressure. Supplementation with nitrate in the diet, using interventions such as beetroot juice, has been shown to reduce blood pressure and improve blood vessel function.

In order for dietary nitrate to have these beneficial effects, it needs to be converted in the body to nitrite, via bacteria that live in the mouth (oral bacteria). Differences in oral bacteria, and how they metabolise nitrate, are thought to influence blood pressure regulation and potentially response to dietary nitrate supplementation.

This study aims to understand (1) whether pregnant women with high blood pressure have a different composition of oral bacteria compared to healthy pregnant women and women who are not pregnant, and (2) how differences in oral bacteria affect blood pressure responses to a dose of dietary nitrate (in the form of beetroot juice).

Study Overview

Status

Unknown

Intervention / Treatment

Study Type

Interventional

Enrollment (Anticipated)

160

Phase

  • Early Phase 1

Contacts and Locations

This section provides the contact details for those conducting the study, and information on where this study is being conducted.

Study Contact

Participation Criteria

Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.

Eligibility Criteria

Ages Eligible for Study

16 years to 45 years (Child, Adult)

Accepts Healthy Volunteers

No

Genders Eligible for Study

Female

Description

Inclusion Criteria:

  • Normotensive or hypertensive women (hypertension as systolic blood pressure >140 mmHg and/or diastolic blood pressure >90 mmHg OR on anti-hypertensive medication)
  • For pregnant women, between 20-28 weeks gestation

Exclusion Criteria:

  • Multi-fetal pregnancy (for pregnant women)
  • Age under 16, or over 45 years of age
  • Lacking ability to consent
  • Pre-existing diabetes (Type 1/Type 2)
  • Previous history of pre-term FGR (delivery before 32 weeks with FGR)
  • Current tobacco smoker
  • Body Mass Index greater than or equal to 40 or less than or equal to 18
  • Use of any of the following drugs in the last 6 months: systemic antibiotics, antifungals, antivirals or antiparasitics (intravenous, intramuscular, or oral)
  • Large doses of commercial probiotics (greater than or equal to 108 cfu or organisms per day) including tablets, capsules, lozenges, chewing gum or powders (ordinary dietary components such as yoghurts do not apply)
  • Evidence of oral disease, assessed on screening proforma (current conditions of: oral candidiasis (thrush); Dental caries (tooth decay); Halitosis; Oral ulcerations/mouth ulcers; Wisdom tooth pain; Chronic dry mouth)
  • Allergy to beetroot juice or lemon juice (both contained within the juice shot)

Study Plan

This section provides details of the study plan, including how the study is designed and what the study is measuring.

How is the study designed?

Design Details

  • Primary Purpose: Basic Science
  • Allocation: Non-Randomized
  • Interventional Model: Single Group Assignment
  • Masking: None (Open Label)

Arms and Interventions

Participant Group / Arm
Intervention / Treatment
Experimental: Normotensive pregnant women
Beetroot juice shot (70mL containing 400mg inorganic nitrate)
Experimental: Hypertensive pregnant women
Beetroot juice shot (70mL containing 400mg inorganic nitrate)
Experimental: Normotensive non-pregnant women
Beetroot juice shot (70mL containing 400mg inorganic nitrate)
Experimental: Hypertensive non-pregnant women
Beetroot juice shot (70mL containing 400mg inorganic nitrate)

What is the study measuring?

Primary Outcome Measures

Outcome Measure
Measure Description
Time Frame
Quantity of oral nitrate reducing bacterial species
Time Frame: Baseline
Assessment of oral bacterial profile using next-generation sequencing (bacterial 16S rRNA sequencing)
Baseline
Oral bacterial nitrate reductase activity
Time Frame: Baseline
Assessment of oral nitrate reductase activity, measured using enzyme assay
Baseline
Difference between groups in nitrate/nitrite concentrations before and after dietary nitrate dose
Time Frame: Baseline to 2.5 hour post-nitrate dose
Measurement of plasma and salivary nitrate and nitrite concentrations, using high-performance liquid chromatography (HPLC)
Baseline to 2.5 hour post-nitrate dose

Secondary Outcome Measures

Outcome Measure
Measure Description
Time Frame
Difference between groups in blood pressure response to dietary nitrate dose
Time Frame: Baseline to 2.5 hour post-nitrate dose
Change in blood pressure
Baseline to 2.5 hour post-nitrate dose

Other Outcome Measures

Outcome Measure
Measure Description
Time Frame
Correlation between salivary nitrate reductase activities and the change in salivary/plasma nitrite concentrations post-nitrate dose
Time Frame: Baseline to 2.5 hour post-nitrate dose
Change in nitrite vs. baseline nitrate reductase activity
Baseline to 2.5 hour post-nitrate dose
Correlation between changes in plasma nitrite concentrations and blood pressure lowering post-nitrate dose
Time Frame: Baseline to 2.5 hour post-nitrate dose
Change in plasma nitrite vs. change in blood pressure
Baseline to 2.5 hour post-nitrate dose

Collaborators and Investigators

This is where you will find people and organizations involved with this study.

Investigators

  • Principal Investigator: Jenny Myers, BM, PhD, Manchester University NHS Foundation Trust

Study record dates

These dates track the progress of study record and summary results submissions to ClinicalTrials.gov. Study records and reported results are reviewed by the National Library of Medicine (NLM) to make sure they meet specific quality control standards before being posted on the public website.

Study Major Dates

Study Start (Anticipated)

May 1, 2019

Primary Completion (Anticipated)

December 1, 2020

Study Completion (Anticipated)

June 1, 2021

Study Registration Dates

First Submitted

April 23, 2019

First Submitted That Met QC Criteria

April 26, 2019

First Posted (Actual)

April 29, 2019

Study Record Updates

Last Update Posted (Actual)

April 29, 2019

Last Update Submitted That Met QC Criteria

April 26, 2019

Last Verified

April 1, 2019

More Information

Terms related to this study

Plan for Individual participant data (IPD)

Plan to Share Individual Participant Data (IPD)?

No

Drug and device information, study documents

Studies a U.S. FDA-regulated drug product

No

Studies a U.S. FDA-regulated device product

No

This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.

Clinical Trials on Gestational Hypertension

Clinical Trials on Beetroot juice

3
Subscribe